Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bezuclastinib - Cogent Biosciences

Next Previous
X
Search
Drug Profile

Bezuclastinib - Cogent Biosciences

Alternative Names: CGT 9486; PLX 9486

Latest Information Update: 05 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plexxikon
  • Developer Cogent Biosciences; Plexxikon
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Systemic mastocytosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastrointestinal stromal tumours
  • Phase II Systemic mastocytosis
  • Phase I/II Solid tumours

Most Recent Events

  • 03 Sep 2024 Cogent Biosciences announces intention to submit NDA to regulatory body for Gastrointestinal stromal tumours and Systemic mastocytosis
  • 03 Sep 2024 Cogent Biosciences completes enrolment in its phase III PEAK trial for Gastrointestinal stromal tumours in Australia, Brazil, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, South Korea, Netherlands, Norway, Spain, Sweden, Taiwan, the US, Argentina, Chile, Czech Republic, Mexico, Poland and the UK
  • 27 Jun 2024 Cogent Biosciences successfully discussed with the US FDA to integrate the Mastocytosis Symptom Severity Daily Diary (MS2D2) into the SUMMIT trial's second part

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top